Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + etoposide + pembrolizumab followed by pembrolizumab + lenvatinib in advanced high-grade neuroendocrine tumors
ISRCTN12812346Phase 2Active, not recruiting
- Sponsor
- Imperial College London
- Start
- Sep 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, etoposide, pembrolizumab and lenvatinib in neuroendocrine carcinoma (NEC), sponsored by Imperial College London. Primary endpoints: Preliminary efficacy by RECIST v1.1, Safety by NCI CTC v5.0 and 1 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on ISRCTN12812346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12812346.